Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008
Date:7/14/2008

r progress in all areas of our business," said Steven W. King, president and CEO of Peregrine. "The most significant developments included initiating, completing enrollment in and reporting positive data for the first set of patients in our first bavituximab Phase II oncology study, entering into a five-year contract potentially worth up to $44.4 million with the Defense Threat Reduction Agency (DTRA) to expedite evaluation of bavituximab for the prevention or treatment of viral hemorrhagic fever infections and achieving significantly increased revenues and an expanded client base at our manufacturing subsidiary Avid. We expect to continue building on these accomplishments during FY 2009 and we are optimistic that the company will achieve even more significant advances during the coming year."

Mr. King continued, "Our most significant product advancements this year were in the bavituximab clinical program. In the anti-cancer program, we were able to start and complete patient enrollment in the planned first set of 15 patients in a Phase II breast cancer trial combining bavituximab and the chemotherapy drug docetaxel. The trial has already met the pre-established primary endpoint with none of the patients having any tumor growth to date and half of the patients achieving an objective tumor response by the first eight-week evaluation point. These are encouraging results and open the door to expanding the trial to an additional planned 31 patients. We also initiated patient enrollment in a second Phase II study combining bavituximab with carboplatin and paclitaxel in patients with advanced lung cancer. A third Phase II study is set to begin shortly testing this same combination in advanced breast cancer patients. In addition, the bavituximab cancer program received significant attention when positive data from an earlier Phase l study was presented at the 2008 ASCO Annual Meeting. These developments have set the stage for what we expect to be additional signific
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers
2. Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
3. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
4. Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
5. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
6. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
7. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
10. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
11. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Continuing its award-winning streak, Nerium International, ... MarCom Awards for outstanding creative achievement by its marketing ... Award, the organization’s top honor, in the Branding category ... in April of this year. The event showcased top ... Nerium was awarded a Gold MarCom Award in the ...
(Date:11/26/2014)... SoundConnect , an award winning ... announce that Darren Suders has joined the team as ... drive the partner program through innovative offerings, ... , Darren brings more than 10-years of channel telecommunication ... channel operations, from policy development, to partner education and ...
(Date:11/26/2014)... MINNEAPOLIS , Nov. 25, 2014 Bio-Techne ... it has appointed Robert Gavin to serve ... of the Protein Platforms Division.  Mr. Gavin will be ... business segment, which includes the ProteinSimple business acquired in ... San Jose, California -based ProteinSimple ...
(Date:11/24/2014)... DUBAI , UAE, November 24, 2014 ... prestigious "Sheikh Hamdan Bin Rashid Al Maktoum Awards for ... in Dubai, United Arab Emirates , ... http://photos.prnewswire.com/prnh/20141124/717861 ) , The Carter Center ... Medical Services is actively involved in numerous programs that ...
Breaking Biology Technology:Nerium International™ Wins One Platinum, Two Gold MarCom Awards 2SoundConnect Appoints Director of Channel Development & Sales 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 3Five US Winners Among Recipients of Hamdan Medical Awards 2
... Netherlands, January 16 Today Top Institute,Pharma announces ... at the,development of a malaria vaccine. This TI ... from previous studies. The project aims to,develop a ... lives of,millions of people in developing countries, especially ...
... for the, Maintenance and Prophylactic Treatment of Asthma in Patients 12 ... ... ALVESCO(R) Will be Commercialised by ... Food and Drug Administration (FDA) approved ALVESCO(R),(ciclesonide) Inhalation Aerosol in the United ...
... ,Center of Excellence, Advancing Performance in ... Patient Outcomes, Costs and Convenience, COSTA MESA, Calif., ... today that it has completed the,previously announced acquisition of Neuro-Therapy ... announced,that Daniel A. Hoffman, MD has been appointed Chief Medical ...
Cached Biology Technology:Boost for Malaria Vaccine Development by Combining Strengths of Dutch and American Researchers 2Boost for Malaria Vaccine Development by Combining Strengths of Dutch and American Researchers 3Boost for Malaria Vaccine Development by Combining Strengths of Dutch and American Researchers 4ALVESCO(R) Gains FDA Approval for the U.S. Market 2ALVESCO(R) Gains FDA Approval for the U.S. Market 3ALVESCO(R) Gains FDA Approval for the U.S. Market 4CNS Response, Inc Completes Neuro-Therapy Clinic Acquisition; Names Daniel A. Hoffman, MD Chief Medical Officer 2CNS Response, Inc Completes Neuro-Therapy Clinic Acquisition; Names Daniel A. Hoffman, MD Chief Medical Officer 3
(Date:11/6/2014)... metastasis, yet progress in preventing and treating migratory ... particularly challenging to design drugs that work against ... biology at Harvard Medical School. , "Unfortunately, ... metastasized." , Gujral and colleagues have now identified ... understand how metastasis begins. Their findings may also ...
(Date:11/5/2014)... show great diversity in their ability to identify scents ... differ in their perceptual evaluation of odors, with women ... , Sex differences in olfactory detection may play ... connected to one,s perception of smell, which is naturally ... superiority has been suggested to be cognitive or emotional, ...
(Date:11/4/2014)... study examining only marketing directed at children on ... has found that the majority of black, middle-income ... marketing tactics. , Authored by Arizona State University ... is the first to examine the use of ... fast food restaurants and its relationship to demographics. ...
Breaking Biology News(10 mins):Migration negation 2Migration negation 3The female nose always knows: Do women have more olfactory neurons? 2Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3
... Aug. 18 Central Florida based locksmith,and safe ... its strategic,alliance with security firm Absolute Access and ... well as all customer service,functions, will be offered ... complete with a new office and showroom location ...
... reported that children with autism have a wide range ... a simple genetic test to identify the disorder. Now, ... reveal correlations in the facial features and brain structures ... enable them to develop a formula for earlier detection ...
... five faculty planning grants to develop long-term research programs ... for fresh water. "Fresh water is crucial to ... than a billion people have no access to safe ... sanitation facilities," said Woods Institute Senior Fellow Richard Luthy, ...
Cached Biology News:Cuellar's Safe and Lock Announces Strategic Alliance with Absolute Access and Security 2Researchers study facial structures, brain abnormalities to reveal formula for detection of autism 2New planning grants to fund research on freshwater issues 2New planning grants to fund research on freshwater issues 3
... Stainless Steel Staining tray 19 x 29 ... staining and blot processing.Automated staining of Coomassie ... nucleic acid analysis. Prepares blots for high ... control of protocol, solution, volume, and processing ...
Complement C1r [Human]...
Cytidine 5'-Triphosphate, Sodium (CTP), 1 g. Category: Nucleotides & Enzymes & Biochemicals, Nucleotides, Additional Nucleotide Products....
... designs oligos for SYBR Green, TaqMan, LNA ... FRET assays. Highly specific primers are designed ... interpreting BLAST search results. Primer efficiency is ... by connecting to the Mfold server. Beacon ...
Biology Products: